Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.74 |
| ▸ | POLB | P06746 | 3/20 | 0.74 |
| ▸ | USP2 | O75604 | 1/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 9/20 | 0.58 |
| ▸ | NPC1 | O15118 | 6/20 | 0.58 |
| ▸ | RAB9A | P51151 | 6/20 | 0.58 |
| ▸ | HTT | P42858 | 4/20 | 0.58 |
| ▸ | CASP3 | P42574 | 2/20 | 0.58 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.58 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.58 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.58 |
| ▸ | MMP2 | P08253 | 1/20 | 0.58 |
| ▸ | MMP9 | P14780 | 1/20 | 0.58 |
| ▸ | MMP8 | P22894 | 1/20 | 0.58 |
| ▸ | MMP13 | P45452 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5213709 | 0.88 | POLB (0.57) | MEN1KMT2APOLBUSP2ALDH1A1 | |
| SCHEMBL271677 | 0.85 | MEN1 (0.74) | MEN1KMT2APOLBUSP2ALDH1A1 | |
| SCHEMBL10752988 | 0.82 | MEN1 (0.70) | MEN1KMT2APOLBUSP2ALDH1A1 | |
| SCHEMBL7035627 | 0.80 | MEN1 (0.67) | MEN1KMT2APOLBUSP2ALDH1A1 | |
| SCHEMBL28291113 | 0.79 | MEN1 (0.65) | MEN1KMT2APOLBUSP2ALDH1A1 | |
| SCHEMBL27991181 | 0.79 | ALDH1A1 (0.71) | MEN1KMT2APOLBUSP2ALDH1A1 | |
| SCHEMBL1171437 | 0.79 | NPC1 (0.82) | MEN1KMT2APOLBALDH1A1TDP1 | |
| SCHEMBL18757895 | 0.78 | TXN (0.70) | MEN1KMT2APOLBUSP2ALDH1A1 | |
| SCHEMBL4328218 | 0.78 | ALDH1A1 (0.69) | MEN1KMT2APOLBUSP2ALDH1A1 | |
| SCHEMBL1541190 | 0.76 | ALDH1A1 (0.67) | MEN1KMT2APOLBUSP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3154976-B1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME (US) | 2019-07-24 | — | — | EP | disclosed |
| EP-3154976-B1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME (US) | 2019-07-24 | — | — | EP | disclosed |
| US-10100064-B2 | Purine inhibitors of human phosphatidylinositol 3-kinase delta | MERCK SHARP & DOHME CORP. (US) | 2018-10-16 | — | — | US | disclosed |
| US-20170114078-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP DOHME CORP. (US) | 2017-04-27 | — | — | US | disclosed |
| US-20170114078-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP DOHME CORP. (US) | 2017-04-27 | — | — | US | disclosed |
| US-20170114078-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP DOHME CORP. (US) | 2017-04-27 | — | — | US | disclosed |
| WO-2015188369-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME CORP. (US) | 2015-12-17 | — | — | WO | disclosed |
| WO-2015188369-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME CORP. (US) | 2015-12-17 | — | — | WO | disclosed |
| US-7307077-B2 | Heterocyclic compound and antitumor agent containing the same as effective ingredient | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2007-12-11 | — | — | US | disclosed |
| CN-101016276-A | 5-nitro-2-difluoromethylbenzimidazole and synthesis method thereof | UNIV SHANGHAI (CN) | 2007-08-15 | — | — | CN | disclosed |
| CN-1310907-C | Heterocyclic compound and antitumour agent containing the same as active ingredient | ZENYAKU KOGYO KK (JP) | 2007-04-18 | — | — | CN | disclosed |
| EP-1389617-B1 | HETEROCYCLIC COMPOUND AND ANTITUMOR AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT | ZENYAKU KOGYO KK (JP) | 2007-01-03 | — | — | EP | disclosed |
| US-20060247232-A1 | Heterocyclic compound and antitumor agent containing the same as effective ingredient | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2006-11-02 | — | — | US | disclosed |
| US-7071189-B2 | Heterocyclic compound and antitumor agent containing the same as active ingredient | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2006-07-04 | — | — | US | disclosed |
| CN-1538967-A | Heterocyclic compound and antitumour agent containing the same as active ingredient | ������ҩ��ҵ��ʽ���� | 2004-10-20 | — | — | CN | disclosed |
| US-20040116421-A1 | Heterocyclic compound and antitumor agent containing the same as active ingredient | OHARA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-17 | — | — | US | disclosed |
| EP-1389617-A1 | HETEROCYCLIC COMPOUND AND ANTITUMOR AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2004-02-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114078-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PI4KA | MEN1 3447/4885KMT2A 4491/4885POLB 277/4885 |
| US-10100064-B2 | Purine inhibitors of human phosphatidylinositol 3-kinase delta | PIK3CD, PIK3CA, PI4KA | MEN1 3447/4885KMT2A 4491/4885POLB 277/4885 |
| US-20060247232-A1 | Heterocyclic compound and antitumor agent containing the same as effective ingredient | CBR3, HCCS, CBR1 | MEN1 1642/4885KMT2A 3803/4885POLB 4594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.